Inhibitory effect of triamcinolone acetonide on corneal neovascularization |
| |
Authors: | Masatoshi Murata Shinji Shimizu Saburo Horiuchi Masayuki Taira |
| |
Institution: | (1) Mitake Eye Clinic, 4-45-19 Aoyama, Morioka City 020-0133, Japan;(2) Department of Biochemistry, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka City 020-8505, Japan;(3) Department of Dental Materials Science and Technology, Iwate Medical University School of Dentistry, 19-1 Uchimaru, Morioka City 020-8505, Japan |
| |
Abstract: | Background Corneal neovascularization (NV) plays an important role in the pathogenesis of corneal disorders. Recently, triamcinolone
acetonide (TA) has been reported as a potential treatment for ocular angiogenesis. However, there are no reports on the inhibitory
effect of TA on the corneal NV.
Methods Triamcinolone acetonide (2 mg) was administered to four rabbits' eyes by a subconjunctival injection immediately after a basic
fibroblast growth factor (bFGF)-pellet was placed into the cornea. As a control, four eyes received an injection of distilled
water. Four weeks later, the inhibition of corneal NV was evaluated as the percentage ratio of the vessel invasion area to
the area that was sandwiched between the pellet and the limbus cornea. To identify the characteristic appearance of new corneal
vessels, the control cornea was examined by using the antibody of vascular endothelial growth factor (VEGF). To confirm TA
concentration in TA-treated corneas, the TA level was measured using high-performance liquid chromatography.
Results Neovascularization from the limbus to the pellet was detected in control eyes 4 weeks after the bFGF pellet implantation.
TA-treated eyes demonstrated the inhibition of the neovascular response to the pellet. The severity of NV as compared between
control and TA-treated eyes was statistically significant (P<0.05). Morphologically, new vessel growth was shown in the control cornea, and endothelial cells of new vessels were positively
stained with the antibody of VEGF. TA concentration in TA-treated corneas at 2 weeks showed 63.5±42.8 μg/g (n=4, mean ± SD), while TA was not detected in control and TA-treated corneas at 4 weeks. The level of TA was effectively maintained
for at least 2 weeks after the subconjunctival injection.
Conclusion We have demonstrated that subconjunctival TA administration inhibited rabbit corneal NV. This agent may prove useful in the
treatment of corneal angiogenic disorders.
No human subjects are involved as experimental animals were used in this study |
| |
Keywords: | Triamcinolone acetonide Corneal neovascularization Vascular endothelial growth factor High-performance liquid chromatography |
本文献已被 SpringerLink 等数据库收录! |
|